Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carole D Mitnick

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
The Journal of Infectious Diseases|October 17, 2006
Are second-line drugs necessary to control multidrug-resistant tuberculosis?Edward A Nardell, Carole D Mitnick
American Journal of Respiratory and Critical Care Medicine|March 23, 2023
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?Carole D Mitnick, Andrew J Nunn
The Lancet. Infectious Diseases|March 27, 2019
Tuberculosis active case-finding: more than just finding casesCarole D Mitnick, Courtney M Yuen
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 15, 2013
Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TBCarole D Mitnick, Joel Keravec, Ted Cohen
American Journal of Respiratory and Critical Care Medicine|July 18, 2017
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility CriteriaFrancis Varaine, Lorenzo Guglielmetti, Carole D Mitnick
The European Respiratory Journal|July 4, 2012
Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?Robert Loddenkemper, Giovanni Sotgiu, Carole D Mitnick
American Journal of Respiratory and Critical Care Medicine|August 10, 2021
The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant TuberculosisCarole D Mitnick, Jennifer J Furin, Catherine Hewison
Plos One|October 19, 2020
Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analysesMeredith B Brooks, Carole D Mitnick, Justin Manjourides
Expert Opinion on Pharmacotherapy|February 5, 2009
Tuberculosis pharmacotherapy: strategies to optimize patient careCarole D Mitnick, Bryan McGee, Charles A Peloquin
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2017
Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape MeetingC Robert Horsburgh, I D Rusen, Carole D Mitnick
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
The Journal of Infectious Diseases|October 17, 2006
Are second-line drugs necessary to control multidrug-resistant tuberculosis?Edward A Nardell, Carole D Mitnick
American Journal of Respiratory and Critical Care Medicine|March 23, 2023
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?Carole D Mitnick, Andrew J Nunn
The Lancet. Infectious Diseases|March 27, 2019
Tuberculosis active case-finding: more than just finding casesCarole D Mitnick, Courtney M Yuen
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 15, 2013
Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TBCarole D Mitnick, Joel Keravec, Ted Cohen
American Journal of Respiratory and Critical Care Medicine|July 18, 2017
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility CriteriaFrancis Varaine, Lorenzo Guglielmetti, Carole D Mitnick
The European Respiratory Journal|July 4, 2012
Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?Robert Loddenkemper, Giovanni Sotgiu, Carole D Mitnick
American Journal of Respiratory and Critical Care Medicine|August 10, 2021
The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant TuberculosisCarole D Mitnick, Jennifer J Furin, Catherine Hewison
Plos One|October 19, 2020
Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analysesMeredith B Brooks, Carole D Mitnick, Justin Manjourides
Expert Opinion on Pharmacotherapy|February 5, 2009
Tuberculosis pharmacotherapy: strategies to optimize patient careCarole D Mitnick, Bryan McGee, Charles A Peloquin
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 28, 2017
Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape MeetingC Robert Horsburgh, I D Rusen, Carole D Mitnick
Pageof 13